Y a-t-il un risque accru de récidive après traitement ?
Oui, le risque de récidive est élevé, nécessitant un suivi régulier après traitement.
RécidiveSuivi médicalCarcinome corticosurrénalien
#5
Le carcinome corticosurrénalien peut-il affecter la qualité de vie ?
Oui, les symptômes et les traitements peuvent significativement impacter la qualité de vie.
Qualité de vieSymptômesCarcinome corticosurrénalien
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du carcinome corticosurrénalien ?
Les antécédents familiaux, certaines maladies génétiques et l'obésité sont des facteurs de risque.
Facteurs de risqueObésitéCarcinome corticosurrénalien
#2
Les maladies génétiques augmentent-elles le risque ?
Oui, des syndromes comme le syndrome de Li-Fraumeni augmentent le risque de ce cancer.
Syndrome de Li-FraumeniGénétiqueCarcinome corticosurrénalien
#3
L'âge est-il un facteur de risque ?
Oui, le carcinome corticosurrénalien est plus fréquent chez les adultes jeunes à moyens.
ÂgeCarcinome corticosurrénalienFacteurs de risque
#4
Le sexe influence-t-il le risque de ce cancer ?
Les femmes sont légèrement plus susceptibles de développer ce cancer que les hommes.
SexeCarcinome corticosurrénalienFacteurs de risque
#5
Le stress a-t-il un impact sur le risque de carcinome ?
Bien que le stress soit un facteur de santé, son lien direct avec ce cancer n'est pas établi.
StressSantéCarcinome corticosurrénalien
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carcinome corticosurrénalien : Questions médicales les plus fréquentes",
"headline": "Carcinome corticosurrénalien : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carcinome corticosurrénalien : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-04",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carcinome corticosurrénalien"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs corticosurrénaliennes",
"url": "https://questionsmedicales.fr/mesh/D000306",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs corticosurrénaliennes",
"code": {
"@type": "MedicalCode",
"code": "D000306",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.344.078.265"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carcinome corticosurrénalien",
"alternateName": "Adrenocortical Carcinoma",
"code": {
"@type": "MedicalCode",
"code": "D018268",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fassnacht",
"url": "https://questionsmedicales.fr/author/Martin%20Fassnacht",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Mainfranken, University of Würzburg, Würzburg, Germany; Central Laboratory, University Hospital Würzburg, Würzburg, Germany."
}
},
{
"@type": "Person",
"name": "Constanze Hantel",
"url": "https://questionsmedicales.fr/author/Constanze%20Hantel",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland; Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Germany."
}
},
{
"@type": "Person",
"name": "Katja Kiseljak-Vassiliades",
"url": "https://questionsmedicales.fr/author/Katja%20Kiseljak-Vassiliades",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Sandra Sigala",
"url": "https://questionsmedicales.fr/author/Sandra%20Sigala",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular & Translational Medicine, Section of Pharmacology, University of Brescia, 25123 Brescia, Italy."
}
},
{
"@type": "Person",
"name": "Jaydira Del Rivero",
"url": "https://questionsmedicales.fr/author/Jaydira%20Del%20Rivero",
"affiliation": {
"@type": "Organization",
"name": "Developmental Therapeutics Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pediatric adrenocortical carcinoma.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36387865",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2022.961650"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas.",
"datePublished": "2022-04-30",
"url": "https://questionsmedicales.fr/article/35499784",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-11626-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adrenocortical carcinoma metastasis. A long story.",
"datePublished": "2022-12-27",
"url": "https://questionsmedicales.fr/article/36655977",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Histopathological Criteria for Paediatric Adrenocortical Carcinoma.",
"datePublished": "2022-05-04",
"url": "https://questionsmedicales.fr/article/35508143",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000524892"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/36444650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOU.0000000000001045"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs des glandes endocrines",
"item": "https://questionsmedicales.fr/mesh/D004701"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de la surrénale",
"item": "https://questionsmedicales.fr/mesh/D000310"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs corticosurrénaliennes",
"item": "https://questionsmedicales.fr/mesh/D000306"
},
{
"@type": "ListItem",
"position": 6,
"name": "Carcinome corticosurrénalien",
"item": "https://questionsmedicales.fr/mesh/D018268"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carcinome corticosurrénalien - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carcinome corticosurrénalien",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carcinome corticosurrénalien",
"description": "Comment diagnostique-t-on un carcinome corticosurrénalien ?\nQuels tests hormonaux sont utilisés pour le diagnostic ?\nQuelle imagerie est la plus courante pour ce cancer ?\nLe diagnostic peut-il être confirmé par une biopsie ?\nQuels signes cliniques peuvent indiquer un carcinome corticosurrénalien ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carcinome corticosurrénalien",
"description": "Quels sont les symptômes courants du carcinome corticosurrénalien ?\nLe carcinome corticosurrénalien cause-t-il des problèmes hormonaux ?\nComment le carcinome corticosurrénalien affecte-t-il le métabolisme ?\nY a-t-il des symptômes spécifiques chez les femmes ?\nLe carcinome corticosurrénalien peut-il causer des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carcinome corticosurrénalien",
"description": "Peut-on prévenir le carcinome corticosurrénalien ?\nQuels facteurs de risque sont associés à ce cancer ?\nLe mode de vie influence-t-il le risque de ce cancer ?\nLes examens réguliers aident-ils à la détection précoce ?\nY a-t-il des vaccins pour prévenir ce cancer ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carcinome corticosurrénalien",
"description": "Quels sont les traitements principaux pour ce cancer ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace pour ce type de cancer ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carcinome corticosurrénalien",
"description": "Quelles sont les complications possibles du carcinome corticosurrénalien ?\nLe carcinome peut-il entraîner des problèmes cardiovasculaires ?\nComment les déséquilibres hormonaux affectent-ils la santé ?\nY a-t-il un risque accru de récidive après traitement ?\nLe carcinome corticosurrénalien peut-il affecter la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carcinome corticosurrénalien",
"description": "Quels sont les principaux facteurs de risque du carcinome corticosurrénalien ?\nLes maladies génétiques augmentent-elles le risque ?\nL'âge est-il un facteur de risque ?\nLe sexe influence-t-il le risque de ce cancer ?\nLe stress a-t-il un impact sur le risque de carcinome ?",
"url": "https://questionsmedicales.fr/mesh/D018268#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un carcinome corticosurrénalien ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, les tests hormonaux et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests hormonaux sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "On mesure les niveaux de cortisol, d'aldostérone et d'androgènes dans le sang."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est la plus courante pour ce cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tomodensitométrie (TDM) est souvent utilisée pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Le diagnostic peut-il être confirmé par une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie permet de confirmer la présence de cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer un carcinome corticosurrénalien ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypertension, la perte de poids et des changements hormonaux peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du carcinome corticosurrénalien ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, hypertension, prise de poids et changements d'humeur."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien cause-t-il des problèmes hormonaux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner un excès de cortisol, provoquant le syndrome de Cushing."
}
},
{
"@type": "Question",
"name": "Comment le carcinome corticosurrénalien affecte-t-il le métabolisme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer une résistance à l'insuline et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les femmes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent présenter des signes d'hyperandrogénie, comme l'hirsutisme."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien peut-il causer des douleurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales ou lombaires peuvent survenir en raison de la tumeur."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le carcinome corticosurrénalien ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à ce cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de ce cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de nombreux cancers, y compris celui-ci."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter des anomalies précoces."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ce cancer ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir le carcinome corticosurrénalien."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux pour ce cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent la première option, mais dépend de l'étendue de la maladie."
}
},
{
"@type": "Question",
"name": "Quand la chimiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent utilisée pour les cas avancés ou inopérables du carcinome."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace pour ce type de cancer ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être utilisée pour réduire la taille de la tumeur ou traiter les métastases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés sont en cours d'étude, mais ne sont pas encore standardisés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du carcinome corticosurrénalien ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation à d'autres organes et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Le carcinome peut-il entraîner des problèmes cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hypertension et d'autres problèmes cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les déséquilibres hormonaux affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des troubles métaboliques, des changements d'humeur et des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de récidive après traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de récidive est élevé, nécessitant un suivi régulier après traitement."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien peut-il affecter la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et les traitements peuvent significativement impacter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du carcinome corticosurrénalien ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, certaines maladies génétiques et l'obésité sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des syndromes comme le syndrome de Li-Fraumeni augmentent le risque de ce cancer."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le carcinome corticosurrénalien est plus fréquent chez les adultes jeunes à moyens."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de ce cancer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes sont légèrement plus susceptibles de développer ce cancer que les hommes."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le risque de carcinome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que le stress soit un facteur de santé, son lien direct avec ce cancer n'est pas établi."
}
}
]
}
]
}
Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Mainfranken, University of Würzburg, Würzburg, Germany; Central Laboratory, University Hospital Würzburg, Würzburg, Germany.
Publications dans "Carcinome corticosurrénalien" :
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland; Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Germany.
Publications dans "Carcinome corticosurrénalien" :
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX, 77030, USA. mahabra@mdanderson.org.
Publications dans "Carcinome corticosurrénalien" :
Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Mainfranken, University of Würzburg, Würzburg, Germany; Central Laboratory, University Hospital Würzburg, Würzburg, Germany.
Publications dans "Carcinome corticosurrénalien" :
Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili of Brescia, 25123 Brescia, Italy.
Publications dans "Carcinome corticosurrénalien" :
Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany. Electronic address: Altieri_B@ukw.de.
Publications dans "Carcinome corticosurrénalien" :
Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany; Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK.
Publications dans "Carcinome corticosurrénalien" :
Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.
Endocrine, Cardiovascular & Metabolic Research, Department of Anatomy, Multidisciplinary Unit for Biomedical Research (UMIB), Instituto de Ciências Biomédicas Abel Salazar, University of Porto (ICBAS/UP), Porto, Portugal.
Publications dans "Carcinome corticosurrénalien" :
Endocrine, Cardiovascular & Metabolic Research, Department of Anatomy, Multidisciplinary Unit for Biomedical Research (UMIB), Instituto de Ciências Biomédicas Abel Salazar, University of Porto (ICBAS/UP), Porto, Portugal.
Publications dans "Carcinome corticosurrénalien" :
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Publications dans "Carcinome corticosurrénalien" :
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Publications dans "Carcinome corticosurrénalien" :
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy of the adrenal gland with an unfavorable prognosis. It is rare in the pediatric population, with an incidence of 0.2-0.3 patients per mill...
Oncocytic adrenocortical neoplasms (OANs) are rare endocrine tumors that present as a spectrum from benign to malignant. The outcomes after surgical resection of the oncocytic variant of adrenocortica...
Adult patients who underwent adrenalectomy for OAN or ACC between January 1990 and September 2020 were identified. Demographics, clinicopathologic factors, American Joint Committee on Cancer stage, an...
Forty-one patients with OAN and 214 patients with ACC were included. The OAN cohort median age was 45.2 years [interquartile ratio (IQR) 38.5-54.0 years], and 61.0% were female. OANs were benign (n = ...
OAN presents as a spectrum from benign indolent tumors to aggressive carcinomas. OACs demonstrate similar clinicopathologic behavior and recurrence-free and overall survival when matched to convention...
Adrenocortical Carcinoma (ACC) is an uncommon adrenal tumor with a predilection for the female population....
A 55-year-old woman was referred to our attention to undergo laparoscopic cholecystectomy for symptomatic gallstone disease. She underwent a left adrenalectomy for ACC 5 years before; the follow-up wa...
This is a very unusual case of double ACC metastases, discovered after the end of standard follow-up and locally treated. The patient is recurrence-free 12 months after these procedures. Minimally inv...
Adrenocortical carcinoma, Cholecystectomy, Liver metastasis, Thermoablation....
Adrenocortical carcinoma (ACC) is diagnosed in paediatric patients at 5 months after symptom onset on average, and 38% die during the first 2.5 years of follow-up. This study aimed to compare the accu...
Data were retrieved from medical records of 57 patients aged <18 years who underwent surgical treatment for ACC with surgical follow-up over 6 months or death due to ACC. They were classified into eit...
The median follow-up duration was 126 (18-225) months in 38 males (66.7%) and 19 females (33.3%) (median age: 3 [1-6.5] years). The good prognosis group was younger than the poor prognosis group (medi...
The Wieneke classification showed the best accuracy but was not sufficiently precise to establish reliable prognosis for ACC in the paediatric population. The Wieneke classification had approximately ...
Adrenocortical carcinoma (ACC) is a rare, aggressive disease with a paucity of data and great variability between published studies regarding its treatment. This review provides information on current...
Complete surgical resection is the only potentially curative treatment for adrenocortical carcinoma (ACC). Adjuvant mitotane treatment is recommended in patients with favourable/intermediate prognosis...
There is scarce evidence for the treatment of ACC, which often complicates clinical decision-making. Patients who progress on EDP-M should be treated in clinical trials....
Spatially resolved metabolomics enables the investigation of tumoral metabolites in situ. Inter- and intratumor heterogeneity are key factors associated with patient outcomes. Adrenocortical carcinoma...
BACKGROUND Hypertensive crisis is a relatively common condition often due to uncontrolled essential hypertension, but also potentially driven by one of many possible secondary etiologies. In this repo...
International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low....
We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000....
time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predict...
In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50-60 Gy (n = 20) or 20-49 Gy (n = 69), stereotactic body RT of 35-50 Gy (SBRT) (n = 36), or brachytherapy of 1...
This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC....
Non-coding RNAs (ncRNAs) are a type of genetic material that do not encode proteins but regulate the gene expression at an epigenetic level, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNA...